Skip to main content

Expression Pathology, NextGen to Offer FFPE Sample Processing and Analysis

NEW YORK (GenomeWeb News) – NextGen Sciences and Expression Pathology will team up to offer protein biomarker services for scientists working with formalin-fixed paraffin-embedded tissue samples, Expression Pathology said today.

The collaborative agreement will allow customers to send their FFPE samples to either company.

Expression Pathology will process samples using its Liquid Tissue MS protein Prep and Director laser micro-dissection technologies. These proteins then will be analyzed for healthy versus diseased or treated versus untreated samples using NextGen’s LC-MS/MS technology.

Immunohistochemistry can take several months to produce antibodies against the proteins, the company said, but the coupled service offering can save time because it does not require antibodies.

“Our combined services will aid in the most challenging task of selecting the appropriate biomarkers for specific drug development programs,” NextGen CEO Mike Pisano said in a statement.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.